MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$32,752K
EPS
-$0.45
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
27,809
16,484
16,245*
21,968
General and administrative
4,747
4,665
5,192*
4,545
Total operating expenses
32,556
21,149
21,437
26,513
Loss from operations
-32,556
-21,149
-21,437*
-26,513
Interest income
1,111
1,064
1,966*
1,639
Interest expense
1,094
1,069
1,053*
1,068
Change in fair value of embedded derivatives
-160
460
260*
-440
Other expense, net
-19
-43
31*
-69
Total other (expense) income
-162
412
1,204*
62
Net loss
-32,718
-20,737
-20,233*
-26,451
Unrealized (gain) loss on marketable securities
-34
-62
-10*
86
Comprehensive loss
-32,752
-20,799
-20,243
-26,365
Basic EPS
-0.45
-0.33
-0.334
-0.44
Diluted EPS
-0.45
-0.33
-0.334
-0.44
Basic Average Shares
72,250,694
63,219,289
60,538,658
60,573,425
Diluted Average Shares
72,250,694
63,219,289
60,538,658
60,573,425
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$32,752K
(20.00%↑ Y/Y)
Net loss
-$32,718K
(20.10%↑ Y/Y)
Unrealized (gain) loss on
marketable securities
-$34K
(-525.00%↓ Y/Y)
Loss from operations
-$32,556K
(22.02%↑ Y/Y)
Total other (expense)
income
-$162K
(-120.25%↓ Y/Y)
Interest income
$1,111K
(-44.86%↓ Y/Y)
Total operating
expenses
$32,556K
(-22.02%↓ Y/Y)
Interest expense
$1,094K
(4.59%↑ Y/Y)
Change in fair value of
embedded derivatives
-$160K
(-300.00%↓ Y/Y)
Other expense, net
-$19K
(85.27%↑ Y/Y)
Research and development
$27,809K
(-25.09%↓ Y/Y)
General and
administrative
$4,747K
(2.64%↑ Y/Y)
Buy us a coffee
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)